Center for Tobacco Control Research and Education, Philip R. Lee Institute for Health Policy Studies, Department of Medicine, University of California, San Francisco , San Francisco, California, USA.
J Psychoactive Drugs. 2020 Sep-Oct;52(4):377-382. doi: 10.1080/02791072.2020.1761040. Epub 2020 May 19.
Cannabis legalization has resulted in rapid commercialization, making this new market increasingly attractive to tobacco, alcohol and beverage, agricultural, and pharmaceutical multinational corporations, who are well positioned to capitalize on the synergy between cannabis and their products. The fact that cannabis remains a Schedule I drug under the Controlled Substances Act is inhibiting research, which consequently prevents evidence-based regulation of modern, more potent, engineered cannabis products and their use. Without a research exemption for legitimate studies of commercially available products, cannabis' Schedule I classification makes it very difficult to conduct medical and scientific research to inform policymaking and regulation. As corporate commercialization looms large, public health organizations need to engage the issue of rapid commercialization of cannabis products and press for evidence-based policies based on public health best practices.
大麻合法化导致了快速的商业化，使这个新市场对烟草、酒精和饮料、农业和制药跨国公司越来越有吸引力，这些公司很容易利用大麻与其产品之间的协同作用。事实上，大麻仍然是《管制物质法》附表 I 中的一种药物，这阻碍了研究，从而妨碍了对现代、更有效力、经过工程设计的大麻产品及其使用进行基于证据的监管。如果没有对商业上可获得的产品进行合法研究的研究豁免，大麻的附表 I 分类使得进行医学和科学研究以为决策和监管提供信息变得非常困难。随着企业商业化的迫近，公共卫生组织需要参与大麻产品快速商业化的问题，并根据公共卫生最佳实践推动基于证据的政策。
